Seniors and Superbugs: The Relationship is Deep New Data Reveals
August 9, 2017
Rise of the Machines: How Artificial Intel and Robotics Are Changing Healthcare
August 12, 2017

Sad senior man in hospital bed and his wife sitting next to him

Spread the love

Infection Control Numbers to Hit $22.58 Billion Globally by 2022 Say Forecasts

Citing a handful of factors – like a ballooning elderly population, rapidly rising HAIs (hospital acquired infections), a growing number of annual surgeries performed, an increase in general demand for better hygiene amongst hospital staff and the general public – market forecasts certainly spell big opportunity for external service providers. They also open a wide and welcoming door for innovation.

For the most part, the infection control market is segmented into two key streams, disinfection and sterilization. Diving deeper, the market is sub-segmented into passive disinfectors such as flushers, washers, personal protective equipment (PPE) and active ones like UV ray-based technology and endoscope reprocessing. All of which are divided by product types and EPA classification. The list of such products can be quite extensive. So to the methods and services options, which can be equally daunting.

All of which potentially leave infection control end-users – pharmaceuticals, bio techs, hospitals, research labs et. al. – in a state easily described as bewilderment. Lacking the right direction and budgets critical to optimizing the way infection control is managed by end-user environments, budgets could be needlessly expended with less than ideal results. Such has already been the case with many organizations, resulting in increased cases of hospital acquired infections and generally dismal progress in curtailing the emergence of a burgeoning superbug population.

Any organization or institution serious about optimizing the efficiency of their infection control initiatives would do well to partner with providers offering guidance and support along with their core services. One particularly prevalent area of expertise in my own company Solaris, is striving to help our partners understand the landscape of options available and the framework of an effective infection control strategy.

Irrespective of any desire, disposition or demand the market may have, one thing is for sure, the potential for big profits in the sector is substantial. Global key players such as 3M Company (US), Advance Sterilization Products (US), Ansell Limited (Australia), Belimed (Swiss), Cantel Medical (US), Getinge Group (Sweden), Halyard Health (US), Hartmann Group (Germany), Sterigenics International, Inc. (US) and Steris Corporation (US), can expect competition from smaller, agile and innovation-focused upstarts such as Solaris to ebb away at market share when the flood gates open.

Which is why we have been busy building a raft full of best-in-class services and solutions for some time now.